Search

everythinglearnresearchcommunity

for

Search:↓

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

Accepting hair loss, with solutions discussed including Minoxidil and Finasteride treatments, shaving the head as a liberating experience, and using beards to make up for lack of hair.

Hair cloning was predicted to be a baldness cure within 3-4 years in 2004, but it has not materialized. Users express frustration and skepticism about the delay.

Hair transplant tips and surgery as a last resort. Discussion includes medications, age considerations, and choosing the right surgeon.

The side effects of taking finasteride as a treatment for hair loss, with particular focus on its sexual and psychiatric side effects; research has indicated that there are high and low outliers in terms of prevalence of sexual side effects, but it is usually between 3-5%, while evidence of lasting sexual side effects comes from lower quality sources.

Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.

The user reversed male pattern baldness using a pro-thyroid diet, lifestyle changes, and scalp stimulation exercises, without Minoxidil or Finasteride. They reported reduced dandruff, itchiness, oiliness, and experienced hair regrowth and thickening over 15 months.

The conversation discusses the scalp tension theory as a potential factor in hair loss, alongside DHT, inflammation, and other mechanisms. Treatments mentioned include finasteride, minoxidil, and botox injections, with some users exploring additional methods due to varying effectiveness.

If oral minoxidil 2.5mg and finasteride 1mg fail after a year, some suggest trying dutasteride. Hair shedding can be normal in the first year, and real changes often occur between 9 months to a year.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.

The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.

The post and conversation discuss Verteporfin's potential as a hair loss treatment. It's shown promise in regrowing hair after transplants and might be effective with microneedling.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

The conclusion of the conversation is that some individuals may experience a condition called reactionary hypergonadism when taking dutasteride for hair loss. This condition can lead to an increase in testosterone levels, which may worsen hair loss instead of improving it.

User Tricky9555 tried various hair loss treatments for 8 months with no visible results. Others suggested considering a hair transplant, checking thyroid levels, and being patient for up to 24 months for potential results.

Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

Pyrilutamide, a potential hair loss treatment that has recently been released for sale, and is thought to have similar efficacy to Dutasteride without side effects. It was discussed in terms of its effectiveness compared to Finasteride, its use by females, and whether it can be safely mixed with RU58841.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

After 11 years on Finasteride, a user's hair is thinning again, suggesting hair may become more sensitive to DHT with age. They plan to introduce Dutasteride once a week, as they cannot tolerate Minoxidil.

The conversation is about the struggles of dealing with diffuse thinning at a young age and the lack of significant improvement after using treatments like finasteride and minoxidil. Some suggest additional methods like derma rolling, microneedling, and hair fibers, while others share their own experiences and encourage persistence with treatment.

The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.

Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.

Dutasteride mesotherapy showed increased hair density and diameter without reducing serum DHT levels in a small study. However, the sample size was too small to make definitive claims about its efficacy.

Hair loss treatments like minoxidil, finasteride, TDM-105795, and PP405. MIT is hosting a hackathon to find innovative hair loss solutions.

Hair cloning is being developed by companies like Kangstem Biotech and Stemson, with potential availability in a few years. Initial costs are expected to be high, but prices may decrease over time.

The conversation is about the interest in testing verteporfin, potentially with a dermaroller, for hair loss treatment. There is frustration over the lack of group buys for promising treatments compared to past efforts with less evidence.